Abstract
To report the results from our phase Ⅱ study of stereotactic body radiotherapy (SBRT) delivering 36 Gy in 4 fractions for patients with localized prostate cancer. From 2015 to 2018, 55 patients were enrolled and treated with SBRT delivering 36 Gy in 4 fractions. Most patients were categorized as intermediate-risk (n = 31) or high-risk (n = 20). The median age was 73 years (range, 54–86). Two-thirds of the patients (n = 37) received androgen deprivation therapy. The median follow-up duration was 30 months. The Radiation Therapy Oncology Group and National Cancer Institute - Common Toxicity Criteria version 4 was used for toxicity assessment. Quality of life (QOL) outcomes were also evaluated using the Expanded Prostate Cancer Index Composite (EPIC). Protocol treatments were completed for all patients. Four patients had biochemical failures. Three patients had clinical failures. One patient died of gastric cancer. The 3-year biochemical control rate was 90.8%. Acute grade 2 genitourinary (GU) and gastrointestinal (GI) toxicities were observed in 5 (9%) and 6 (11%) patients, respectively. No grade 3 or higher acute toxicities were observed. Late grade 2 GU and GI toxicities were observed in 6 (11%) and 5 (9%) patients, respectively. One patient (1.8%) had late grade 3 GU toxicity (radiation cystitis) 2.5 years after treatment. EPIC scores slightly decreased during the acute phase and recovered 3 months after treatment. Our phase II study showed that SBRT delivering 36 Gy in 4 fractions was safe and effective with favorable QOL outcomesTabled 1Abstract 2614; Table; Patient-reported outcomes assessed by Expanded Prostate Cancer Index Compositepre2w1m3m6m9m12m18m24mUrinary83.69 (12.20)66.57 (25.52)85.79 (15.21)90.44 (18.34)92.00 (11.68)88.62 (17.06)87.39 (17.01)87.39 (17.07)82.79 (22.50)Bowel89.93 (11.00)89.93 (11.00)80.18 (20.17)88.04 (12.02)89.63 (12.58)88.44 (11.89)88.45 (10.19)89.76(8.68)88.02 (10.34)Sexual33.57 (12.61)31.39 (12.64)31.84 (5.64)32.34 (10.31)31.37 (7.85)30.08 (7.07)32.45 (13.22)33.00 (9.28)32.06 (8.34)Hormone84.37 (17.20)80.16 (19.19)87.06 (12.82)88.04 (12.55)89.46 (11.96)89.86 (9.33)90.63 (12.41)88.92 (11.74)93.54 (9.78)mean (SD) Open table in a new tab
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call